Jim Cramer turns bullish on health care stock after years of doubt

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become synonymous with the pandemic trade, and Cramer’s enthusiasm faded as demand for Covid-era vaccines dried ...

CryptoAlerta — análise de criptomoedas e mercado em tempo real